Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in high-grade glioma or glioblastoma
NCT04937413Phase 1Completed
- Sponsor
- Duke University
- Start
- Oct 2021
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evolocumab in glioblastoma (GBM) and malignant glioma, sponsored by Duke University. Primary endpoint: Presence of evolocumab in surgical tumor tissue. Started Oct 2021; status: completed.
02
Drugs
evolocumab
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on NCT04937413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04937413.